keyword
MENU ▼
Read by QxMD icon Read
search

Serous carcinoma

keyword
https://www.readbyqxmd.com/read/29049607/dose-response-association-of-cd8-tumor-infiltrating-lymphocytes-and-survival-time-in-high-grade-serous-ovarian-cancer
#1
Ellen L Goode, Matthew S Block, Kimberly R Kalli, Robert A Vierkant, Wenqian Chen, Zachary C Fogarty, Aleksandra Gentry-Maharaj, Aleksandra Toloczko, Alexander Hein, Aliecia L Bouligny, Allan Jensen, Ana Osorio, Andreas D Hartkopf, Andy Ryan, Anita Chudecka-Glaz, Anthony M Magliocco, Arndt Hartmann, Audrey Y Jung, Bo Gao, Brenda Y Hernandez, Brooke L Fridley, Bryan M McCauley, Catherine J Kennedy, Chen Wang, Chloe Karpinskyj, Christiani B de Sousa, Daniel G Tiezzi, David L Wachter, Esther Herpel, Florin Andrei Taran, Francesmary Modugno, Gregg Nelson, Jan Lubinski, Janusz Menkiszak, Jennifer Alsop, Jenny Lester, Jesús García-Donas, Jill Nation, Jillian Hung, José Palacios, Joseph H Rothstein, Joseph L Kelley, Jurandyr M de Andrade, Luis Robles-Díaz, Maria P Intermaggio, Martin Widschwendter, Matthias W Beckmann, Matthias Ruebner, Mercedes Jimenez-Linan, Naveena Singh, Oleg Oszurek, Paul R Harnett, Peter F Rambau, Peter Sinn, Philipp Wagner, Prafull Ghatage, Raghwa Sharma, Robert P Edwards, Roberta B Ness, Sandra Orsulic, Sara Y Brucker, Sharon E Johnatty, Teri A Longacre, Ursula Eilber, Valerie McGuire, Weiva Sieh, Yanina Natanzon, Zheng Li, Alice S Whittemore, Anna deFazio, Annette Staebler, Beth Y Karlan, Blake Gilks, David D Bowtell, Estrid Høgdall, Francisco J Candido Dos Reis, Helen Steed, Ian G Campbell, Jacek Gronwald, Javier Benítez, Jennifer M Koziak, Jenny Chang-Claude, Kirsten B Moysich, Linda E Kelemen, Linda S Cook, Marc T Goodman, María José García, Peter A Fasching, Stefan Kommoss, Suha Deen, Susanne K Kjaer, Usha Menon, James D Brenton, Paul D P Pharoah, Georgia Chenevix-Trench, David G Huntsman, Stacey J Winham, Martin Köbel, Susan J Ramus
Importance: Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors. Objective: To define the prognostic role of CD8+ TILs in epithelial ovarian cancer. Design, Setting, and Participants: This was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium...
October 12, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29045296/taking-the-tube-from-normal-fallopian-tube-epithelium-to-ovarian-high-grade-serous-carcinoma
#2
Alicia A Tone
Detailed pathologic studies over the past decade suggest a distal fallopian tube origin for the majority of "ovarian" high-grade serous carcinomas (HGSC). This review will summarize molecular alterations observed in tubal precursors for HGSC, namely p53 signatures and serous tubal intraepithelial carcinomas, and in nonmalignant fallopian tube epithelial cells obtained from women at increased genetic risk for HGSC. Recent experiments investigating the impact of follicular fluid exposure and retrograde menstruation on tumor development in the fallopian tube will also be discussed...
December 2017: Clinical Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29042553/molecular-analysis-of-high-grade-serous-ovarian-carcinoma-with-and-without-associated-serous-tubal-intra-epithelial-carcinoma
#3
Jennifer Ducie, Fanny Dao, Michael Considine, Narciso Olvera, Patricia A Shaw, Robert J Kurman, Ie-Ming Shih, Robert A Soslow, Leslie Cope, Douglas A Levine
Many high-grade serous carcinomas (HGSCs) of the pelvis are thought to originate in the distal portion of the fallopian tube. Serous tubal intra-epithelial carcinoma (STIC) lesions are the putative precursor to HGSC and identifiable in ~ 50% of advanced stage cases. To better understand the molecular etiology of HGSCs, we report a multi-center integrated genomic analysis of advanced stage tumors with and without STIC lesions and normal tissues. The most significant focal DNA SCNAs were shared between cases with and without STIC lesions...
October 17, 2017: Nature Communications
https://www.readbyqxmd.com/read/29039611/altered-expression-of-different-galnac%C3%A2-transferases-is-associated-with-disease-progression-and-poor-prognosis-in-women-with-high-grade-serous-ovarian-cancer
#4
Razan Sheta, Magdalena Bachvarova, Marie Plante, Jean Gregoire, Marie-Claude Renaud, Alexandra Sebastianelli, Ion Popa, Dimcho Bachvarov
Protein glycosylation perturbations are implicated in a variety of diseases, including cancer. Aberrant glycosylation in cancer is frequently attributed to altered expression of polypeptide GalNAc transferases (GalNAc‑Ts) - enzymes initiating mucin-type O-glycosylation. A previous study from our group demonstrated that one member of this family (GALNT3) is overexpressed in epithelial ovarian cancer (EOC), and GALNT3 expression correlated with shorter progression-free survival (PFS) in EOC patients with advanced disease...
October 9, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/29038585/tissue-and-plasma-levels-of-galectins-in-patients-with-high-grade-serous-ovarian-carcinoma-as-new-predictive-biomarkers
#5
Marilyne Labrie, Lorenna Oliveira Fernandes De Araujo, Laudine Communal, Anne-Marie Mes-Masson, Yves St-Pierre
Galectins are moving closer to center stage in detecting glycosylation aberration in cancer cells. Here, we have investigated the expression of galectins in ovarian cancer (OC) and examined their potential as biomarkers in tissues and blood plasma samples of high grade serous ovarian carcinoma (HGSC) patients. In tissues, we found that increased protein expression of stromal gal-1 and epithelial gal-8/9 was associated with a poor response to treatment of HGSC patients. Gal-8/9 were both independent predictors of chemoresistance and overall survival (OS), respectively...
October 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29034552/cervical-carcinomas-with-a-micropapillary-component-a-clinicopathological-study-of-8-cases
#6
Colin J R Stewart, M H E Koay, Connull Leslie, Nathan Acott, Yee C Leung
AIMS: Micropapillary carcinomas, or carcinomas with a micropapillary component, are well-recognised in the breast and other anatomical sites. However, they have seldom been described in the cervix. In this report we present a clinicopathological analysis of eight cervical tumours that showed at least a focal (≥5%) component of micropapillary carcinoma. METHODS AND RESULTS: The study group comprised eight cervical carcinomas (4 adenocarcinomas and 4 adenosquamous carcinomas) with a micropapillary component...
October 16, 2017: Histopathology
https://www.readbyqxmd.com/read/29031505/-histological-and-molecular-classification-of-endometrial-carcinoma-and-therapeutical-implications
#7
REVIEW
Catherine Genestie, Alexandra Leary, Mojgan Devassoux-Shisheboran, Aurélie Auguste
Endometrial cancer is the fourth cause of cancer in women in France and is the second most common cancer of the gynecologic cancer after breast cancer with 7275 new cases in 2012. The incidence of this neoplasm tends to increase with population aging, diabetes and obesity's augmentation. In rare cases, a hereditary factor has been described: Lynch's syndrome. The therapeutic management of the patient depends on the endometrial biopsy which specifies the histological type and the histo-prognostic grade as well as the MRI which allow the tumor staging...
October 11, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/29028099/the-diagnostic-value-of-determination-of-serum-golph3-associated-with-ca125-ca19-9-in-patients-with-ovarian-cancer
#8
H-Y Fan, D-M Duan, Y-F Liu
OBJECTIVE: To evaluate the value of three tumor markers serum Golgi phosphoprotein-3 (GOLPH3), cancer antigen 125 (CA125) and cancer antigen 19-9 (CA19.9) in the diagnosis and postoperative evaluation of ovarian cancer by detecting these three markers. PATIENTS AND METHODS: A total of 187 patients were studied and included in the ovarian cancer group, benign pelvic mass group, and the normal control group. The levels of serum Golgi phosphoprotein-3 (GOLPH3), cancer antigen 125 (CA125) and cancer antigen 199 (CA19...
September 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29027536/kras-mutation-of-extraovarian-implants-of-serous-borderline-tumor-prognostic-indicator-for-adverse-clinical-outcome
#9
Tao Zuo, Serena Wong, Natalia Buza, Pei Hui
In contrast to non-invasive extraovarian implants, invasive implants of ovarian serous borderline tumor/atypical proliferative serous tumor are associated with adverse outcome and have been reclassified as low-grade serous carcinoma. Mutations of KRAS and/or BRAF have been reported in up to 50% of serous borderline tumor/atypical proliferative serous tumor. We investigated KRAS and BRAF mutation frequencies in the two types of implants of serous borderline tumor/atypical proliferative serous tumor in correlation with clinical outcome...
October 13, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/29024544/squamous-cell-carcinoma-in-serous-effusions-avoiding-pitfalls-in-this-rare-encounter
#10
Christopher LePhong, Elizabeth W Hubbard, Stuart Van Meter, Laurentia Nodit
BACKGROUND: With advent of personalized medicine, precise classification of malignant tumors becomes essential. Squamous cell carcinoma (SCC) is rarely found in serous effusions and has morphologic and immunohistochemical (IHC) overlap with other neoplasms. METHODS: 17-year review identified 49 fluids from 26 patients where SCC was recognized. RESULTS: SCC was more frequent in pleural fluid (84%) and rare in other effusions. Lung SCC was common (65%), followed by head and neck (16%), with other origins less represented...
October 11, 2017: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/29019871/despite-diagnostic-morphology-many-mixed-endometrial-carcinomas-show-unexpected-immunohistochemical-staining-patterns
#11
Cathleen E Matrai, Edyta C Pirog, Lora Hedrick Ellenson
Historically, endometrial carcinomas have been classified primarily according to their histology. However, the use of immunohistochemistry has become commonplace in their evaluation, particularly in diagnostically challenging cases. Our objective was to evaluate mixed endometrial carcinomas using a well-established panel of biomarkers to assess the consistency and utility of these stains in clinical diagnosis. Eighteen cases comprised of various combinations of classical serous (SC), endometrioid (EC), clear cell (CC) morphologies were identified and subjected to a panel of immunohistochemical markers including p53, p16, Ki67, estrogen receptor, progesterone receptor, and Napsin A...
October 10, 2017: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/29019869/the-analysis-of-cell-cycle-related-proteins-in-ovarian-clear-cell-carcinoma-versus-high-grade-serous-carcinoma
#12
Yukiko Hazama, Takuya Moriya, Mika Sugihara, Rikiya Sano, Mitsuru Shiota, Takafumi Nakamura, Koichiro Shimoya
In Japan, the frequency of ovarian clear cell carcinoma (CCC) is twice as high as that in the United States and Europe. Often, patient prognosis of CCC is poor because of chemoresistance. Here, we focus on the cell cycle, which is one of the mechanisms of chemoresistance. To detect the informative markers and improve the strategy of chemotherapy for CCC, we performed immunochemical staining of cell cycle-related proteins in ovarian malignant tumors. We detected that each of the 29 samples of CCC and high-grade serous carcinoma (HGSC) were necessary to reveal the significant differences in immunostaining and prognosis...
October 10, 2017: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/29017668/frequency-of-her2-neu-protein-expression-in-ovarian-epithelial-cancers
#13
Anum Jafri, Sarwat Rizvi
OBJECTIVE: To detect the frequency of Her-2/neu protein expression in epithelial ovarian cancers by immunohistochemistry. STUDY DESIGN: Descriptive cross-sectional study. PLACE AND DURATION OF STUDY: Department of Pathology, King Edward Medical University, Lahore, from July 2014 to May 2015. METHODOLOGY: Fifty-six cases diagnosed as epithelial ovarian cancer on histopathology were included in this study. Immunohistochemistry was performed to observe the pattern of HER2/neu protein expression in these cases...
September 2017: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/28992761/kras-mutation-testing-in-borderline-ovarian-tumors-and-low-grade-ovarian-carcinomas-with-a-rapid-fully-integrated-molecular-diagnostic-system
#14
Pawel Sadlecki, Paulina Antosik, Dariusz Grzanka, Marek Grabiec, Malgorzata Walentowicz-Sadlecka
Epithelial ovarian neoplasms are a heterogeneous group of tumors, including various malignancies with distinct clinicopathologic and molecular features. Mutations in BRAF and KRAS genes are the most frequent genetic aberrations found in low-grade serous ovarian carcinomas and serous and mucinous borderline tumors. Implementation of targeted therapeutic strategies requires access to highly specific and highly sensitive diagnostic tests for rapid determination of mutation status. One candidate for such test is fully integrated, real-time polymerase chain reaction-based Idylla™ system for quick and simple detection of KRAS mutations in formaldehyde fixed-paraffin embedded tumor samples...
October 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28990983/pathology-of-ovarian-cancer-recent-insights-unveiling-opportunities-in-prevention
#15
Friedrich Kommoss, C Blake Gilks
Ovarian carcinomas were formerly referred to as "surface epithelial carcinomas," reflecting the belief that they all arise from the ovarian surface epithelium. It is now appreciated that most ovarian carcinomas originate from either fallopian tube or endometriotic epithelium, and how we approach prevention will thus differ between histotypes. The 5 histotypes of ovarian carcinoma (high-grade serous, clear cell, endometrioid, mucinous, and low-grade serous, in descending order of frequency) can be reproducibly diagnosed, and are distinct disease entities, differing with respect to genetic risk factors, molecular events during oncogenesis, patterns of spread, and response to chemotherapy...
December 2017: Clinical Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28989055/down-regulation-of-hectd3-by-her2-inhibition-makes-serous-ovarian-cancer-cells-sensitive-to-platinum-treatment
#16
Tong Shu, Yi Li, Xiaowei Wu, Bin Li, Zhihua Liu
Resistance to platinum-based chemotherapy is a major cause of treatment failure in patients with epithelial ovarian cancer and predicts a poor prognosis. Previously, we found that HECTD3 confers cancer cell resistance to apoptosis. However, the significance of HECTD3 expression in ovarian cancer and its regulatory mechanisms were unknown. Here, we found that HECTD3 depletion promotes carboplatin-induced apoptosis in both an ovarian cancer cell model and a xenograft mouse model. Moreover, high HECTD3 expression is significantly associated with poor platinum response and prognosis in ovarian cancer patients...
October 6, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28984301/are-the-uterine-serous-carcinomas-underdiagnosed-histomorphologic-and-immunohistochemical-correlates-and-clinical-follow-up-in-high-grade-endometrial-carcinomas-initially-diagnosed-as-high-grade-endometrioid-carcinoma
#17
Shaomin Hu, Jeff L Hinson, Rahul Matnani, Michael L Cibull, Rouzan G Karabakhtsian
Histologic subclassification of high-grade endometrial carcinomas can sometimes be a diagnostic challenge when based on histomorphology alone. Here we utilized immunohistochemical markers to determine the immunophenotype in histologically ambiguous high-grade endometrial carcinomas that were initially diagnosed as pure or mixed high-grade endometrioid carcinoma, aiming to determine the utility of selected immunohistochemical panel in accurate classification of these distinct tumor types, while correlating these findings with the clinical outcome...
October 6, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28984201/identification-of-common-oncogenic-and-early-developmental-pathways-in-the-ovarian-carcinomas-controlling-by-distinct-prognostically-significant-microrna-subsets
#18
Vladimir A Kuznetsov, Zhiqun Tang, Anna V Ivshina
BACKGROUND: High-grade serous ovarian carcinoma (HG-SOC) is the dominant tumor histologic type in epithelial ovarian cancers, exhibiting highly aberrant microRNA expression profiles and diverse pathways that collectively determine the disease aggressiveness and clinical outcomes. However, the functional relationships between microRNAs, the common pathways controlled by the microRNAs and their prognostic and therapeutic significance remain poorly understood. METHODS: We investigated the gene expression patterns of microRNAs in the tumors of 582 HG-SOC patients to identify prognosis signatures and pathways controlled by tumor miRNAs...
October 3, 2017: BMC Genomics
https://www.readbyqxmd.com/read/28983627/systematic-module-approach-identifies-altered-genes-and-pathways-in-four-types-of-ovarian-cancer
#19
Jing Liu, Hui-Ling Wang, Feng-Mei Ma, Hong-Ping Guo, Ning-Ning Fang, Shan-Shan Wang, Xin-Hong Li
The present study aimed to identify altered genes and pathways associated with four histotypes of ovarian cancer, according to the systematic tracking of dysregulated modules of reweighted protein‑protein interaction (PPI) networks. Firstly, the PPI network and gene expression data were initially integrated to infer and reweight normal ovarian and four types of ovarian cancer (endometrioid, serous, mucinous and clear cell carcinoma) PPI networks based on Spearman's correlation coefficient. Secondly, modules in the PPI network were mined using a clique‑merging algorithm and the differential modules were identified through maximum weight bipartite matching...
September 28, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28977941/ccne1-expression-in-high-grade-serous-carcinoma-does-not-correlate-with-chemoresistance
#20
Stav Sapoznik, Sarit Aviel-Ronen, Keren Bahar-Shany, Oranit Zadok, Keren Levanon
Delayed diagnosis of ovarian cancer, as well as high recurrence rates and lack of personalized therapy options, are among the causes for poor survival figures. Much effort is made towards developing new therapeutic possibilities, however predictive biomarkers are still unavailable. CCNE1 amplification, occurring in ∼20% of the high grade serous ovarian tumors, was previously proposed as a marker for platinum resistance and poor prognosis as well as for CDK2 inhibition. The current study aimed to examine the role of CCNE1 positive-immunostain as a predictor of first-line taxane-platinum chemoresistance...
September 22, 2017: Oncotarget
keyword
keyword
95673
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"